Caroline C (Cole) Block MD

Oncology•Boston, MA

Breast Cancer

Physician

Join to View Full Profile

Dana-Farber Cancer Center450 Brookline AveBoston, MA 02215
Phone+1 617-632-3800

Summary

Dr. Caroline Block is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute. She received her medical degree from University of Michigan Medical School and has been in practice 32 years. She specializes in breast cancer.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1988 - 1990
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1985 - 1988
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1986 - 1987
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1985 - 1986
University of Michigan Medical SchoolClass of 1985

Certifications & Licensure

MA State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
ACTIVE_NOT_RECRUITING
PHASE3
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2009 Jun 01
Completed
Phase 1, Phase 2
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
ACTIVE_NOT_RECRUITING
PHASE3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
The Young Women's Breast Cancer Study Start of enrollment: 2006 Nov 01
Active, not recruiting
Study of Vitamin D in Untreated Metastatic Colorectal Cancer Start of enrollment: 2012 Apr 13
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
ACTIVE_NOT_RECRUITING
PHASE3
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study.
Ilana Schlam, Kelly A Hirko, Daniela Shveid, Inas Abuali, Sarah Sewaralthahab
JCO Global Oncology. 2024-12-01
2 citations
Design and Implementation of an Opt-Out, End-to-End, PreemptiveTesting Program for Patients Planned for a Systemic Fluoropyrimidine.
Joseph O Jacobson, Garrett Rompelman, Angela Chen, Samantha Morrison-Ma, Lindsay Murray
JCO Oncology Practice. 2024-08-01
13 citations
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Horm...
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma
Journal of Clinical Oncology. 2024-06-10

Professional Memberships

American Society of Clinical Oncology - ASCO
Member